Laboratory Medicine ›› 2020, Vol. 35 ›› Issue (12): 1243-1247.DOI: 10.3969/j.issn.1673-8640.2020.12.009
Previous Articles Next Articles
XU Kaihong(), MU Qitian, OUYANG Guifang, YAN Xiao
Received:
2020-08-04
Online:
2020-12-30
Published:
2020-12-31
CLC Number:
XU Kaihong, MU Qitian, OUYANG Guifang, YAN Xiao. Cytogenetic analysis of 153 newly-diagnosed cases of multiple myeloma[J]. Laboratory Medicine, 2020, 35(12): 1243-1247.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2020.12.009
细胞遗传学异常类型 | 例数 | 超二倍体 | 非超二倍体 |
---|---|---|---|
数目和结构异常 | 30 | 13 | 17 |
仅数目异常 | 7 | 5 | 2 |
仅结构异常 | 6 | 0 | 6 |
合计 | 43 | 18 | 25 |
细胞遗传学异常类型 | 例数 | 超二倍体 | 非超二倍体 |
---|---|---|---|
数目和结构异常 | 30 | 13 | 17 |
仅数目异常 | 7 | 5 | 2 |
仅结构异常 | 6 | 0 | 6 |
合计 | 43 | 18 | 25 |
序号 | 年龄/岁 | 性别 | ISS分期 | 染色体核型 | PFS/年 |
---|---|---|---|---|---|
1 | 68 | 女 | Ⅲ期 | 52,X,-X,+3,+5,+7,+9,+15,del(19)(q11),add(20)(q13), +21,+mar[4]/46,XX[16] | 2.2 |
2 | 76 | 男 | Ⅲ期 | 52~54,XY,+der(1)(q21),+5×2,del(5)(q21),der(6)(q23), +9×2,der(11)(p13),der(12)(q24),+19,+20,+21[10]/46, XY[10] | 2.7(OS) |
3 | 67 | 女 | Ⅲ期 | 47,XX,add(4)(q21),add(5)(p10),-8,+18,+mar[2]/47,idem, der(3)(q28)[3]/46,XX[19] | 1.9 |
4 | 54 | 男 | Ⅲ期 | 54,XY,+6,+7,der(8)(q24),+9×2,add(11)(p15),+15, +mar1,+mar2,+mar3[2]/46,XY[22] | 2.3 |
5 | 58 | 女 | Ⅱ期 | 46,XX,t(3;17)(q28;q11)[3]/46,XX[17] | 1.7 |
6 | 83 | 男 | Ⅲ期 | 46,XY,der(11)(p15)[4]/46,XY[6] | 1.5(OS) |
7 | 64 | 男 | Ⅱ期 | 46,XY,del(12)(p11p12)[2]/46,XY[18] | 2.1 |
8 | 65 | 女 | Ⅱ期 | 49,XX,+5,+9,add(12)(p12),+mar[5]/46,XX[15] | >4.1 |
9 | 43 | 男 | Ⅱ期 | 46,XY,add(10)(q22),der(12)(q24)[2]46,XY[18] | >3.4 |
序号 | 年龄/岁 | 性别 | ISS分期 | 染色体核型 | PFS/年 |
---|---|---|---|---|---|
1 | 68 | 女 | Ⅲ期 | 52,X,-X,+3,+5,+7,+9,+15,del(19)(q11),add(20)(q13), +21,+mar[4]/46,XX[16] | 2.2 |
2 | 76 | 男 | Ⅲ期 | 52~54,XY,+der(1)(q21),+5×2,del(5)(q21),der(6)(q23), +9×2,der(11)(p13),der(12)(q24),+19,+20,+21[10]/46, XY[10] | 2.7(OS) |
3 | 67 | 女 | Ⅲ期 | 47,XX,add(4)(q21),add(5)(p10),-8,+18,+mar[2]/47,idem, der(3)(q28)[3]/46,XX[19] | 1.9 |
4 | 54 | 男 | Ⅲ期 | 54,XY,+6,+7,der(8)(q24),+9×2,add(11)(p15),+15, +mar1,+mar2,+mar3[2]/46,XY[22] | 2.3 |
5 | 58 | 女 | Ⅱ期 | 46,XX,t(3;17)(q28;q11)[3]/46,XX[17] | 1.7 |
6 | 83 | 男 | Ⅲ期 | 46,XY,der(11)(p15)[4]/46,XY[6] | 1.5(OS) |
7 | 64 | 男 | Ⅱ期 | 46,XY,del(12)(p11p12)[2]/46,XY[18] | 2.1 |
8 | 65 | 女 | Ⅱ期 | 49,XX,+5,+9,add(12)(p12),+mar[5]/46,XX[15] | >4.1 |
9 | 43 | 男 | Ⅱ期 | 46,XY,add(10)(q22),der(12)(q24)[2]46,XY[18] | >3.4 |
[1] | LIWING J,UTTERVALL K,LUND J,et al.Improved survival in myeloma patients:starting to close in on the gap between elderly patients and a matched normal population[J]. Br J Haematol,2014,164(5):684-693. |
[2] | ABDALLAH N,RAJKUMAR S V,GREIPP P,et al.Cytogenetic abnormalities in multiple myeloma:association with disease characteristics and treatment response[J]. Blood Cancer J,2020,10(8):82-87. |
[3] | SONNEVELD P,AVET-LOISEAU H,LONIAL S,et al.Treatment of multiple myeloma with high-risk cytogenetics:a consensus of the International Myeloma Working Group[J]. Blood,2016,127(24):2955-2962. |
[4] | AGNELLI L,TASSONE P,NERI A.Molecular profiling of multiple myeloma:from gene expression analysis to next-generation sequencing[J]. Expert Opin Biol Ther,2013,13(Suppl 1):S55-S68. |
[5] | RACK K,VIDREQUIN S,DARGENT J L.Genomic profiling of myeloma:the best approach,a comparison of cytogenetics,FISH and array-CGH of 112 myeloma cases[J]. J Clin Pathol,2016,69(1):82-86. |
[6] | MCGOWAN-JORDAN J,SIMONS A,SCHMID M.An international system for human cytogenomic nomenclature[M]. Switzerland: S Karger AG,2016. |
[7] | VAN WIER S,BRAGGIO E,BAKER A,et al.Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma[J]. Haematologica,2013,98(10):1586-1592. |
[8] | ZANDECKI M,LAÏ J L,FACON T.Multiple myeloma:almost all patients are cytogenetically abnormal[J]. Br J Haematol,1996,94(2):217-227. |
[9] | RADOCHA J,MAISNAR V,POUR L,et al.Validation of multiple myeloma risk stratification indices in routine clinical practice:analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies[J]. Cancer Med,2018,7(8):4132-4145. |
[10] | LU J,LU J,CHEN W,et al.Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma:results of a multicenter analysis[J]. Blood Cancer J,2014,4(8):e239. |
[11] | BYUN J M,SHIN D Y,HONG J,et al.Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response:redefining high-risk multiple myeloma in Asian patients[J]. Cancer Med,2018,7(3):831-841. |
[12] | MIKULASOVA A,SMETANA J,WAYHELOVA M,et al.Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance[J]. Eur J Haematol,2016,97(6):568-575. |
[13] | MOHAMED A N,BENTLEY G,BONNETT M L,et al.Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes[J]. Am J Hematol,2007,82(12):1080-1087. |
[14] | MERZ M,JAUCH A,HIELSCHER T,et al.Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma[J]. Blood Adv,2017,2(1):1-9. |
[15] | KUMAR S,FONSECA R,KETTERLING R P,et al.Trisomies in multiple myeloma:impact on survival in patients with high-risk cytogenetics[J]. Blood,2012,119(9):2100-2105. |
[16] | CHRETIEN M L,CORRE J,LAUWERS-CANCES V,et al.Understanding the role of hyperdiploidy in myeloma prognosis:which trisomies really matter?[J]. Blood,2015,126(25):2713-2719. |
[17] | CARBALLO-ZARATE A A,MEDEIROS L J,FANG L,et al. Additional-structural-chromosomal aberrations are associated with inferior clinical outcome in patients with hyperdiploid multiple myeloma:a single-institution experience[J]. Mod Pathol,2017,30(6):843-853. |
[18] | DURU A D,SUTLU T,WALLBLOM A,et al.Deletion of chromosomal region 8p21 confers resistance to bortezomib and is associated with upregulated decoy TRAIL receptor expression in patients with multiple myeloma[J]. PLoS One,2015,10(9):e0138248. |
[19] | GLITZA I C,LU G,SHAH R,et al.Chromosome 8q24.1/c-MYC abnormality:a marker for high-risk myeloma[J]. Leuk Lymphoma,2015,56(3):602-607. |
[1] | HAN Xue, WEN Liu, WAN Yang. Analysis of amniotic fluid chromosome karyotype and genome copy number variation in critical or high-risk pregnant women by Down's screening [J]. Laboratory Medicine, 2023, 38(6): 548-552. |
[2] | YI Wei, PAN Yunhua, LIU Houchang, YU Chongfei, YANG Biqing, GE Shijun, LIN Keqin, CHU Jiayou, YANG Zhaoqing. Application of whole exome sequencing in 9p deletion syndrome [J]. Laboratory Medicine, 2022, 37(6): 539-542. |
[3] | SUN Hengjuan, DU Chengkan, LI Hong, LIU Min, ZHANG Hong. Diagnostic value of cytogenetics in acute leukemia with MLL gene abnormality [J]. Laboratory Medicine, 2022, 37(12): 1196-1199. |
[4] | WANG Hongling, LI Li, ZHANG Chunling, LIN Lihui, DING Jing, LI Huidan, WEI Daolin, BAI Ping. Retrospective clinical analysis of κ light chain multiple myeloma with cytoplasmic granules [J]. Laboratory Medicine, 2021, 36(8): 818-822. |
[5] | ZHANG Yi, WANG Zengge, WANG Jian. Progress in laboratory diagnosis of rare diseases [J]. Laboratory Medicine, 2021, 36(2): 122-129. |
[6] | CHEN Xia, CHEN Xi. Clinical significance of plasma protein C and von Willebrand factor in patients with multiple myeloma [J]. Laboratory Medicine, 2021, 36(11): 1110-1113. |
[7] | ZHANG Xiaohui, TAO Chaoxin, BAI Mingming, CHEN Lei, ZHANG Yuna, DU Huijuan, XING Jiangtao, ZHU Yun. Morphological and clinical characteristics of near-tetraploid acute lymphocytic leukemia [J]. Laboratory Medicine, 2020, 35(7): 645-650. |
[8] | ZHENG Wei, LU Jie, GUI Qingrong, WANG Dongyun. Laboratory examination results and clinical characteristics of 28 cases of IgD multiple myeloma [J]. Laboratory Medicine, 2020, 35(3): 224-228. |
[9] | ZHENG Wei, LU Jie, HAO Aijun, ZHANG Yinhui. Analysis on the laboratory examination results of 5 cases of diclonal multiple myeloma [J]. Laboratory Medicine, 2019, 34(8): 710-716. |
[10] | HU Wenjing, CHEN Qinfang, WU Yi, HAN Xu, GUO Xiaokui, TAO Jiong. Application of a modified copy number variation detection technique in spontaneous miscarriage heredity [J]. Laboratory Medicine, 2019, 34(7): 637-642. |
[11] | YU Xia, SHI Mingfang, WANG Shuangjie, ZHOU Yuanyuan, LIANG Xiuyun. Analysis of prenatal gene determination results in 91 couples with same type thalassemia [J]. Laboratory Medicine, 2019, 34(3): 240-243. |
[12] | ZHANG Jingyu, FAN Hong, LU Bingtong, HU Haitao. Serum immunoglobulin and other factors on the effect of blood separating in separator gel tubes [J]. Laboratory Medicine, 2018, 33(4): 275-278. |
[13] | JI Wei, WU Hongkun, ZHOU Lin. Research progress of non-coding RNA in multiple myeloma [J]. Laboratory Medicine, 2018, 33(3): 264-268. |
[14] | ZHU Jianfeng, WANG Beili, GUO Wei, PAN Baishen. Clinical characteristics of a case of near-tetraploidy acute myeloid leukemia [J]. Laboratory Medicine, 2017, 32(7): 652-655. |
[15] | ZHANG Jingyu, CHEN Lixin, WANG Lifang, HU Haitao, WANG Jun, FAN Hong. Influence of serum IgA level on serum fructosamine level [J]. Laboratory Medicine, 2017, 32(3): 182-184. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||